Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 7, 2009, Pages 1270-1274

  Benyamina, Amine ^a,b,c   Bonhomme Faivre, Laurence ^b,c   Picard, Valérie ^d   Sabbagh, Audrey ^a   Richard, Damien ^d   Blecha, Lisa ^a,b,c   Rahioui, Hassan ^c   Karila, Laurent ^b,c   Lukasiewicz, Michael ^a,b,c   Farinotti, Robert ^b   Picard, Véronique ^b   Marill, Catherine ^a,b,c   Reynaud, Michel ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

ABCB1; Cannabis; Dependence; P glycoprotein; Polymorphism

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MALE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; ODDS RATIO; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STATISTICS, NONPARAMETRIC; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 69349094638     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.07.016     Document Type: Article

References (34)

1. Agrawal A., and Lynskey M.T. The genetic epidemiology of cannabis use, abuse and dependence. Addiction 101 6 (2006) 801-812
2. Alenius M., Wadelius M., Dahl M.L., Hartvig P., Lindstrom L., and Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res (2007)
3. Anthony J.C., Warner L.A., and Kessler R.C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 2 (1994) 244-268
4. Aryana A., and Williams M.A. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty?. Int J Cardiol 118 2 (2007) 141-144
5. Azarpira N., Aghdaie M.H., Behzad-Behbahanie A., Geramizadeh B., Behzadi S., Malekhoseinie S.A., et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp Clin Transplant 4 1 (2006) 416-419
6. Bonhomme-Faivre L., Benyamina A., Reynaud M., Farinotti R., and Abbara C. Disposition of delta(9) tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict Biol (2008)
7. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 3 (2001) 169-174
8. Chowbay B., Li H., David M., Cheung Y.B., and Lee E.J. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60 2 (2005) 159-171
9. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., and Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27 8 (1999) 866-871
10. Fu Q., Heath A.C., Bucholz K.K., Nelson E., Goldberg J., Lyons M.J., et al. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: contribution of antisocial personality disorder in men. Arch Gen Psychiatry 59 12 (2002) 1125-1132
11. Goldman D., Oroszi G., and Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet 6 7 (2005) 521-532
12. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 7 (2000) 3473-3478
13. Jeannesson E., Albertini L., Siest G., Gomes A.M., Ribeiro V., Aslanidis C., et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol 21 4 (2007) 411-418
14. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455 1 (1976) 152-162
15. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., Ikenaga Y., et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32 2 (2008) 398-404
16. Kendler K.S. "A gene for...": the nature of gene action in psychiatric disorders. Am J Psychiatry 162 7 (2005) 1243-1252
17. Kenny P.J. Brain reward systems and compulsive drug use. Trends Pharmacol Sci 28 3 (2007) 135-141
18. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 5811 (2007) 525-528
19. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 5335 (1997) 52-58
20. Kreek M.J., Bart G., Lilly C., LaForge K.S., and Nielsen D.A. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57 1 (2005) 1-26
21. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13 8 (2003) 481-494
22. Leschziner G.D., Andrew T., Pirmohamed M., and Johnson M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7 3 (2007) 154-179
23. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 95 2 (2002) 153-164
24. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Jama 264 19 (1990) 2511-2518
25. Reid M.J., and Bornheim L.M. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol 61 11 (2001) 1357-1367
26. Substance Abuse and Mental Health Services Administration (2006) Results from the 2006 National Survey on Drug Use and Health: National Findings. In: Studies, OoA (Ed.), NSDUH Series H-30 Rockville, MD: NSDUH.
27. Tetrault J.M., Crothers K., Moore B.A., Mehra R., Concato J., and Fiellin D.A. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 167 3 (2007) 221-228
28. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., and Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36 1 (1995) 1-6
29. Turgut G., Kurt E., Sengul C., Alatas G., Kursunluoglu R., Oral T., et al. Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Mol Biol Rep (2007)
30. Uhl G.R. Molecular genetics of substance abuse vulnerability: remarkable recent convergence of genome scan results. Ann N Y Acad Sci 1025 (2004) 1-13
31. United Nations Office of Drug Control (2007) 2007 World Drug Report. In: Publications, UN (Ed.), (pp. 282): UNODC.
32. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., and Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15 10 (2005) 693-704
33. Wilker A. Dynamics of drug dependence: implications of a conditioning theory for research and treatment. Arch Gen Psychiatry 28 (1973) 611-616
34. Williams J., and Skeels C. The impact of cannabis use on health. De Economist 154 (2006) 517-546